Literature DB >> 17453818

Downregulation of missing in metastasis gene (MIM) is associated with the progression of bladder transitional carcinomas.

Ying Wang1, Jiali Liu, Elizabeth Smith, Kang Zhou, Jie Liao, Guang-Yu Yang, Ming Tan, Xi Zhan.   

Abstract

Missing in metastasis (MIM) gene encodes a putative metastasis suppressor. However, the role of MIM in tumorigenesis and metastasis has not yet been established. Western blot analysis using a MIM specific antibody demonstrated that MIM protein is present at varying levels in a variety of normal cells as well as tumor cell lines. Immunohistochemical staining of adult mouse tissues revealed abundant MIM immunoreactivity in uroepithelial cells in the bladder, neuron Purkinje cells in the cerebellum, and megakaryocytes in the bone marrow and spleen in addition. MIM immunoreactivity also was found in human normal bladder transitional epithelial cells. However, the reactivity was not seen in 69 percent of human primary transitional cell carcinoma specimens. Over 51 percent of the tumors at low grade display MIM staining similarly to the normal cells, whereas only 16.7 percent of the tumors at high-grade with poor differentiation show faint or mild staining. Furthermore, full-length MIM protein is highly expressed in SV-HUC-L an immortalized normal transitional epithelial cell line, moderately expressed in T24 and poorly expressed in J82 and TCCSUP transitional cell carcinoma cells. This finding indicates that downegulation of MIM expression may correlate with the transition of tumor cells from distinct epithelium-like morphology to less differentiated carcinomas.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17453818     DOI: 10.1080/07357900701205457

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  19 in total

1.  Dimerization is necessary for MIM-mediated membrane deformation and endocytosis.

Authors:  Meng Cao; Tailan Zhan; Min Ji; Xi Zhan
Journal:  Biochem J       Date:  2012-09-15       Impact factor: 3.857

2.  BAR proteins in cancer and blood disorders.

Authors:  Yolande Chen; Jorie Aardema; Ashish Misra; Seth J Corey
Journal:  Int J Biochem Mol Biol       Date:  2012-05-18

3.  Changes in tumor growth and metastatic capacities of J82 human bladder cancer cells suppressed by down-regulation of calreticulin expression.

Authors:  Yi-Chien Lu; Chiung-Nien Chen; Bojeng Wang; Wen-Ming Hsu; Szu-Ta Chen; King-Jen Chang; Cheng-Chi Chang; Hsinyu Lee
Journal:  Am J Pathol       Date:  2011-06-30       Impact factor: 4.307

4.  Role of Akt2 in regulation of metastasis suppressor 1 expression and colorectal cancer metastasis.

Authors:  E Agarwal; C M Robb; L M Smith; M G Brattain; J Wang; J D Black; S Chowdhury
Journal:  Oncogene       Date:  2017-01-09       Impact factor: 9.867

5.  MTSS1 overexpression correlates with poor prognosis in colorectal cancer.

Authors:  Ding Wang; Mei-rong Xu; Tao Wang; Ting Li; Jian wei Zhu
Journal:  J Gastrointest Surg       Date:  2011-05-12       Impact factor: 3.452

6.  Metastasis tumour suppressor-1 and the aggressiveness of prostate cancer cells.

Authors:  Noha Mustafa; Tracey A Martin; Wen G Jiang
Journal:  Exp Ther Med       Date:  2010-12-02       Impact factor: 2.447

7.  Mice deficient in MIM expression are predisposed to lymphomagenesis.

Authors:  D Yu; X H Zhan; X F Zhao; M S Williams; G B Carey; E Smith; D Scott; J Zhu; Y Guo; S Cherukuri; C I Civin; X Zhan
Journal:  Oncogene       Date:  2011-11-14       Impact factor: 9.867

8.  Cortactin is implicated in murine zygotic development.

Authors:  Dan Yu; Helin Zhang; Thomas A Blanpied; Elizabeth Smith; Xi Zhan
Journal:  Exp Cell Res       Date:  2009-12-30       Impact factor: 3.905

9.  I-BAR protein antagonism of endocytosis mediates directional sensing during guided cell migration.

Authors:  Gabriel A Quinones; Janet Jin; Anthony E Oro
Journal:  J Cell Biol       Date:  2010-04-12       Impact factor: 10.539

10.  Downregulation of metastasis suppressor 1(MTSS1) is associated with nodal metastasis and poor outcome in Chinese patients with gastric cancer.

Authors:  Ke Liu; Gefang Wang; Houzhong Ding; Ying Chen; Guanzhen Yu; Jiejun Wang
Journal:  BMC Cancer       Date:  2010-08-15       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.